MOUNTAIN VIEW, CA--(Marketwired - January 29, 2015) - VIVUS, Inc. (VVUS) today announced that the European Commission (EC) has adopted the commission implementing decision amending the marketing ...

Vivus has signed up Italy's Menarini to sell its recently-approved erectile dysfunction drug Spedra in over 40 European countries, plus Australia and New Zealand. Vivus has signed up Italy’s Menarini ...

MOUNTAIN VIEW, Calif., Dec. 12, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that it has entered into a License and Commercialization Agreement with Sanofi to commercialize ...

SINGAPORE--(BUSINESS WIRE)--Mitsubishi Tanabe Pharma Corporation (TSE: 4508), and Singapore-based A. Menarini Asia-Pacific Holdings Pte Ltd (“Menarini AP”) have entered into a licensing agreement to ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Spedra (Vivus BV) for the treatment of erectile dysfunction ...

Mitsubishi Tanabe Pharma Corporation and Singapore-based A. Menarini Asia-Pacific Holdings Pte Ltd (Menarini AP) have entered into a licensing agreement to commercialise and promote Spedra (avanafil).

L'accordo riguarda la fornitura in oltre 40 Paesi europei, oltre che in Australia e in Nuova Zelanda. Vivus riceverà un pagamento iniziale e varie milestones di pagamento sulla base delle approvazioni ...

The European Association of Urology 2014 guidelines on male sexual dysfunction define erectile dysfunction as the persistent inability to attain and maintain an erection sufficient to permit ...

VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual ...

SINGAPORE--(BUSINESS WIRE)--Mitsubishi Tanabe Pharma Corporation (TSE: 4508), and Singapore-based A. Menarini Asia-Pacific Holdings Pte Ltd (“Menarini AP”) have entered into a licensing agreement to ...